Want to see CH:MEDX full AI Analyst Report?
MEDX Stock Chart & Stats
CHF9.12
CHF0.32(2.96%)
At close: 4:00 PM EST
CHF9.12
CHF0.32(2.96%)
Day’s Range― - ―
52-Week RangeCHF7.61 - CHF12.86
Previous CloseN/A
Volume22.50K
Average Volume (3M)115.75K
Market Cap
CHF339.59M
Enterprise ValueCHF680.66
Total Cash (Recent Filing)CHF113.90M
Total Debt (Recent Filing)CHF330.30M
Price to Earnings (P/E)49.3
Beta0.99
Next Earnings
Feb 23, 2027EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend Yield1.27%
Share Statistics
EPS (TTM)0.16
Shares Outstanding41,262,370
10 Day Avg. Volume183,978
30 Day Avg. Volume115,752
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.5
Revenue Forecast (FY)CHF446.92M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables And Customer Stickinessmedmix's business includes recurring sales of consumables and replacement components tied to installed systems. That consumable revenue base creates repeatable cash flows, raises customer switching costs (especially in regulated healthcare), and supports multi-year revenue visibility and margin stability.
Diversified End‑market ExposureServing healthcare, consumer and industrial markets reduces reliance on any single cyclical segment. Healthcare exposure brings higher qualification barriers and longer product lifecycles, while industrial and consumer sales smooth demand volatility, collectively supporting more durable revenue streams.
Positive Operating And Free Cash FlowThe company generates positive operating and free cash flow, which funds operations, dividend payments and investments without immediate equity raises. Although FCF fell ~36% YoY, sustained positive cash conversion provides financial resilience and the ability to manage capex and working capital over the medium term.
Bears Say
Revenue Trending DownRevenues have declined or stagnated in recent years, with 2025 down ~4%. Continued top-line weakness constrains operating leverage, limits scale benefits, and can pressure margins and reinvestment capacity. If demand or order momentum doesn't recover, growth may remain constrained for months.
Thin Profitability And Low ROENet margins near 1% and a ROE around 1.5% indicate limited profitability relative to capital employed. This weak return profile reduces ability to accumulate retained earnings, fund expansion internally or sustain a high payout, and leaves the company vulnerable to margin erosion from cost or pricing pressure.
Leverage Near Parity With EquityDebt roughly equals equity (D/E ~0.92) and has risen, which reduces financial flexibility. With thin margins and volatile FCF, higher leverage increases interest and refinancing risk, limits room for M&A or cyclical cushioning, and could constrain strategic investments over the medium term.
medmix AG News
MEDX FAQ
What was medmix AG’s price range in the past 12 months?
medmix AG lowest stock price was CHF7.61 and its highest was CHF12.86 in the past 12 months.
What is medmix AG’s market cap?
medmix AG’s market cap is CHF339.59M.
When is medmix AG’s upcoming earnings report date?
medmix AG’s upcoming earnings report date is Feb 23, 2027 which is in 214 days.
How were medmix AG’s earnings last quarter?
medmix AG released its earnings results on Jul 23, 2026. The company reported CHF0.35 earnings per share for the quarter, the consensus estimate of CHF0.35 by CHF0.
Is medmix AG overvalued?
According to Wall Street analysts medmix AG’s price is currently Overvalued.
Does medmix AG pay dividends?
medmix AG pays a Annually dividend of CHF0.1 which represents an annual dividend yield of 1.27%. See more information on medmix AG dividends here
What is medmix AG’s EPS estimate?
medmix AG’s EPS estimate is 0.43.
How many shares outstanding does medmix AG have?
medmix AG has 41,262,370 shares outstanding.
What happened to medmix AG’s price movement after its last earnings report?
medmix AG reported an EPS of CHF0.35 in its last earnings report, expectations of CHF0.35. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of medmix AG?
Currently, no hedge funds are holding shares in CH:MEDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
medmix AG
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.
Technical Analysis
Rieter Holding AG
―
Komax Holding AG
―
―
Mikron Holding AG
―
StarragTornos Group AG
―